Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) announced its earnings results on Thursday. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.04, Zacks reports. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 82.92% and a negative net margin of 102.34%.

Cellectis Stock Performance

Shares of NASDAQ:CLLS traded up $0.15 during midday trading on Friday, reaching $2.84. The company’s stock had a trading volume of 24,095 shares, compared to its average volume of 16,107. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13. The stock has a fifty day moving average of $2.95 and a 200 day moving average of $3.48. Cellectis has a twelve month low of $2.35 and a twelve month high of $5.48. The firm has a market capitalization of $284.97 million, a PE ratio of -4.37 and a beta of 2.91.

Analyst Ratings Changes

A number of research analysts have issued reports on CLLS shares. Citizens Jmp reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. Finally, Barclays began coverage on Cellectis in a research report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Institutional Investors Weigh In On Cellectis

Hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC acquired a new position in shares of Cellectis in the 4th quarter valued at about $34,000. Virtu Financial LLC acquired a new stake in Cellectis during the third quarter worth about $72,000. Acadian Asset Management LLC raised its position in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares in the last quarter. Millennium Management LLC lifted its holdings in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the period. Finally, Marshall Wace LLP boosted its position in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.